Press Releases

Date Title and Summary View
Oct 15, 2004
MacroGenics Completes Series B Financing
MacroGenics Completes Series B Financing For Immediate Release Rockville, MD, October 15, 2004  MacroGenics, Inc., a growing biotechnology company developing antibodies and vaccines to treat cancer, autoimmune disorders, and infectious diseases, announced the completion of its Series B financing of
Additional Formats
Apr 26, 2004
Neose Technologies and MacroGenics Sign Research Collaboration and License Agreement
CONTACTS: For Neose Technologies, Inc. Robert I. Kriebel - Sr. VP & CFO (215) 315-9000 Barbara Krauter - Manager (215) 315-9000 For MacroGenics Michael Richman - Exec. VP & CFO (301) 354-0681   For Immediate Release April 26, 2004 HORSHAM, Pa. , and ROCKVILLE , Md.
Additional Formats
Oct 29, 2003
Genzyme, MacroGenics Announce Joint Effort to Develop New Therapies for Immune-Mediated Diseases
CONTACTS: For Genzyme Sally Curley (investors) (617) 591-7140 Dan Quinn (media) (617) 591-5849 For MacroGenics Michael Richman (301) 354-0681   For Immediate Release October 29, 2003 CAMBRIDGE, Mass. and Rockville, Md . Genzyme Corp. (Nasdaq: GENZ) and MacroGenics, Inc.
Additional Formats
Sep 04, 2003
HHS Names UTMB, Seven Others as New Regional Centers To Focus on Biodefense Research
HHS Names UTMB, Seven Others as New Regional Centers To Focus on Biodefense Research The Department of Health and Human Services (HHS) today announced that the University of Texas Medical Branch at Galveston (UTMB) is among eight institutions nationwide receiving grants totaling approximately $350
Additional Formats
Jun 07, 2002
MacroGenics Acquires Eliance, Inc., and Establishes Partnership in Immunotherapeutics with UT Southwestern.

$12.6 Million in Financing Completed

Additional Formats
Apr 01, 2002
MacroGenics Announces Senior Appointments
MacroGenics Announces Senior Appointments Rockville, MD April 1, 2002 - MacroGenics, Inc., a biotechnology company that is developing immunotherapeutics for treating cancer and inflammatory diseases, announced two key appointments to the senior management team. Michael S.
Additional Formats
Sep 25, 2001
MacroGenics Raises $13.5 Million and Appoints President and CEO

Former MedImmune Senior Vice President joins MacroGenics; Company completes key license agreements and closure of second tranche of Series A financing, bringing total raised to $13.5MM.

Additional Formats